Singapore Attracts Pharmaceutical Manufacturing Investment - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Singapore Attracts Pharmaceutical Manufacturing Investment
Singapore moves forward with a plan to diversify its life science investment with projects in biologics and drug discovery.


Pharmaceutical Technology
Volume 32, Issue 1

Biotechnology investment in Singapore

As the pharmaceutical industry shifts its emphasis to biologics, Singapore is also keeping pace to build its biopharmaceutical base. "Having established a reputation as one of the world's most competitive and trusted sites for producing small-molecule-based active pharmaceutical ingredients and final dosage forms, Singapore is now aggressively pursuing biologics manufacturing investments, especially since biologics is anticipated to be a key growth driver for the global industry," say Yeoh. "We are quickly building up a critical mass of biologics manufacturing investments and expect to maintain this momentum as we attract more companies to set up such manufacturing facilities there." He points to five major biologics manufacturing investments (Lonza, GSK Biologicals, Genentech, and Novartis) that total more than US$1.5 billion.

Yeoh points out the first phase of Singapore's BMS initiative, which was from 2000-2005, focused on putting key building blocks by establishing core capabilities in biomedical research and introducing human and industrial capital. "For the next phase (2006-2010), we are building on this foundation and strengthening our capabilities in translational and clinical research to bring discoveries from the bench to the bedside and the marketplace and ultimately improve human healthcare," says Yeoh. That effort involves further expansion of its industry R&D base and an increase in the number of companies undertaking the discovery and development of new drugs and medical devices in Singapore.

For more on this topic, see:

Manufacturing Investment in Puerto Rico

Pharmaceutical and Biopharmaceutical Manufacturing Advances in Ireland


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
8%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: Pharmaceutical Technology,
Click here